statistiche ricercatore

Continente	#
NA - Nord America	544
AS - Asia	433
EU - Europa	296
SA - Sud America	63
Continente sconosciuto - Info sul continente non disponibili	21
AF - Africa	18
Totale	1.375

Nazione	#
US - Stati Uniti d'America	533
SG - Singapore	163
VN - Vietnam	92
CN - Cina	76
IT - Italia	62
IE - Irlanda	52
BR - Brasile	45
DE - Germania	33
HK - Hong Kong	32
SE - Svezia	25
BD - Bangladesh	24
AT - Austria	22
NL - Olanda	20
FI - Finlandia	18
FR - Francia	18
GB - Regno Unito	16
ZA - Sudafrica	15
IN - India	10
AR - Argentina	6
CA - Canada	6
EC - Ecuador	5
IQ - Iraq	5
RU - Federazione Russa	5
IR - Iran	4
PK - Pakistan	4
PL - Polonia	4
BE - Belgio	3
CZ - Repubblica Ceca	3
ES - Italia	3
MX - Messico	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
AL - Albania	2
CI - Costa d'Avorio	2
KG - Kirghizistan	2
LT - Lituania	2
MK - Macedonia	2
NP - Nepal	2
PY - Paraguay	2
SA - Arabia Saudita	2
TH - Thailandia	2
TR - Turchia	2
UA - Ucraina	2
UZ - Uzbekistan	2
AZ - Azerbaigian	1
BG - Bulgaria	1
BH - Bahrain	1
BO - Bolivia	1
DZ - Algeria	1
HN - Honduras	1
HR - Croazia	1
ID - Indonesia	1
JO - Giordania	1
JP - Giappone	1
KR - Corea	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
NO - Norvegia	1
PH - Filippine	1
RS - Serbia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	1.354

Nome	#
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab	208
Stage III and metastatic Lymph Node Ratio are the only independent prognostic factors in colorectal signet-ring cell carcinoma patients	167
Should patients on levothyroxine therapy be screened for pancreatic cancer?	157
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer	157
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity	155
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer	130
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study	110
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5)	99
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals	97
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review	95
Totale	1.375

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	23	0	1	2	0	1	0	7	1	1	0	1	9
2022/2023	205	10	28	9	15	10	19	6	18	66	4	11	9
2023/2024	106	8	7	6	3	7	19	9	7	1	8	9	22
2024/2025	300	17	11	12	25	26	32	17	17	26	36	28	53
2025/2026	679	70	38	78	64	98	49	64	18	92	53	28	27
2026/2027	27	15	12	0	0	0	0	0	0	0	0	0	0
Totale													1.375